Infosys completes acquisition of BASE life science
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
It is high time that India assumed a leadership role in healthcare.
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Bharat Swasth Mahotsav organises ‘Padma Doctors Congregation’ for Celebrating Healthcare Changemakers in India Since Independence
Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Therapy recently approved in Canada under the brand name KORSUVA
Subscribe To Our Newsletter & Stay Updated